Enzo Biochem/ENZ

$1.15

-0.86%
-
1D1W1MYTD1YMAX

About Enzo Biochem

Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.

Ticker

ENZ

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Kara Cannon

Employees

179

Headquarters

Farmingdale, United States

Enzo Biochem Metrics

BasicAdvanced
$59.42M
Market cap
1.73
P/E ratio
$0.67
EPS
0.73
Beta
-
Dividend rate
$59.42M
0.72522
$2.74
$1.16
103.29K
3.201
2.892
0.331
4.993
-26.56%
-45.01%
-39.5%
1.729
1.811
0.828
0.84
346.55%
3.15%
-25.8%

Enzo Biochem Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-35.29% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$8.5M
8.97%
Net income
$-3M
-54.55%
Profit margin
-35.29%
-58.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Enzo Biochem stock?

Enzo Biochem (ENZ) has a market cap of $59.42M as of April 17, 2024.

What is the P/E ratio for Enzo Biochem stock?

The price to earnings (P/E) ratio for Enzo Biochem (ENZ) stock is 1.73 as of April 17, 2024.

Does Enzo Biochem stock pay dividends?

No, Enzo Biochem (ENZ) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Enzo Biochem dividend payment date?

Enzo Biochem (ENZ) stock does not pay dividends to its shareholders.

What is the beta indicator for Enzo Biochem?

Enzo Biochem (ENZ) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Enzo Biochem stock price target?

The target price for Enzo Biochem (ENZ) stock is $, which is 100% below the current price of $1.15. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Enzo Biochem stock

Buy or sell Enzo Biochem stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing